Japanese Bioventure JCR Develops Transplant Cellular Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan's JCR Pharmaceuticals, with the help of Mochida Pharmaceutical, has in two phases of trials, a treatment aimed at reducing the side effects of bone marrow transplants. JCR, a bioventure, has the cellular therapy JR-031 in Phase I and Phase II trials simultaneously. The treatment involves cultured human mesenchymal stem cells taken from the spinal fluid of healthy people and injected into a transplant patient. The work is being done in cooperation with Mochida and JCR expects to complete both sets of trials in 2011. If successful, JR-031 would be Japan's first cellular therapy. (Click here for more - a subscription may be required
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.